Paul Fletcher

Title: Paul Fletcher: Innovator in Peptide Therapeutics

Introduction

Paul Fletcher is a notable inventor based in Cheshire, CT (US), recognized for his contributions to the field of peptide therapeutics. His innovative work focuses on insulin and insulin-like growth factor receptors, which are crucial for various biological processes.

Latest Patents

Fletcher holds a patent for "Insulin and IGF-1 receptor agonists and antagonists." This patent discloses peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity. The invention identifies at least two different binding sites present on these receptors, which selectively bind the peptides. As agonists, these peptides may be developed as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics, showcasing the potential for significant advancements in medical treatments.

Career Highlights

Throughout his career, Paul Fletcher has worked with prominent companies in the biotechnology sector, including Antyra Inc. and Novo Nordisk A/S. His experience in these organizations has contributed to his expertise in peptide research and development.

Collaborations

Fletcher has collaborated with talented individuals in his field, including Renuka Pillutla and Olga Dedova. These partnerships have likely enhanced his research and innovation efforts.

Conclusion

Paul Fletcher's work in peptide therapeutics represents a significant advancement in the understanding and treatment of conditions related to insulin and IGF-1 receptors. His innovative patent and collaborations highlight his commitment to improving therapeutic options in the medical field.